FindTrial
Sign In

pembrolizumab (KEYTRUDA® )

DRUG2 trials

Sponsors

Eikon Therapeutics

Conditions

Advanced MelanomaAdvanced Solid TumorsEndometrial CancerMSI-H or dMMR Advanced Solid TumorsMSI-H/dMMR Colorectal CancerMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction CancerMismatch Repair Deficient or MSI-High Solid Tumors

Phase 1

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
RecruitingNCT07262619
Eikon TherapeuticsAdvanced Solid Tumors, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors +4
Start: 2026-01-22End: 2029-03-01Target: 160Updated: 2026-03-02

Phase 2

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
RecruitingNCT06697301
Eikon TherapeuticsAdvanced Melanoma
Start: 2025-05-22End: 2040-12-31Target: 740Updated: 2025-11-12